Users Discontinuing Slimming Medications Regain Pounds Four Times Faster Compared to Those on Conventional Diets

New research reveals that individuals who come off blockbuster weight-loss injections like semaglutide or tirzepatide may regain shed pounds far faster than those who stop conventional lifestyle plans.

Published data in a prominent medical journal points out that while obese individuals can lose a large proportion of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.

"Individuals purchasing such medications must be informed of the danger of rapid weight regain when the therapy ends," warns lead investigator Dr. Susan Jebb.

This pace of regain implies a return to starting mass within about 18 months.

Analyzing Therapies

The analysis, which reviewed 37 of studies involving thousands of participants, contrasted the outcomes of GLP-1 agonists with older methods.

The team note that people who shed pounds through lifestyle changes alone generally see a slower weight regain—approximately 100 grams monthly—once they finish.

Understanding the Quick Regain

Experts suggest the way of the jabs explains the accelerated rebound.

GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.

"Long-term administration of GLP-1 concentrations several times higher than normal may cause the body to produce less of its own natural hormone, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics researcher.

"Withdrawal of this hormone supplement means hunger is uncontrolled, making excessive eating a significant risk."

A Chronic Issue?

Medical guidelines advise the injections for people with obesity-related health risks, alongside recommended diet and exercise modifications.

Many experts contend that, due to the significant potential of relapse, the therapy is often ongoing.

This view is supported by drug manufacturers, who note that the results "highlight the chronic character of excess weight," comparing it to managing conditions like diabetes.

Patient Accounts

People who have come off the jabs describe a powerful return of hunger.

"I experienced something flipping and you're instantly ravenous," described one woman.

This difficulty is worsened if patients have not developed lasting lifestyle or habit changes during therapy.

Growing Adoption

Figures suggest that a significant number of people in the UK have used these injections in the last 12 months, with interest being substantial.

• Use is more common among women compared to males.
• The middle-aged age group shows the greatest usage rates.
• Many obtain the medications through private prescriptions rather than the NHS.

Finally, experts stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent fix and long-term success relies on combined behavioural support.